Rolf Billeskov, Post doc

Infektionsimmunologi , Vaccineforskning & Udvikling

Statens Serum Institut
Artillerivej 5 , 81/348
2300 København S
3268 3268

Telefon:

32688144

E-mail:

Ansvarsområder

Pre-clinical development and testing of new vaccines and vaccine strategies against tuberculosis

Analysis of immune response during different stages of experimental Mycobacterium tuberculosis infection in mice
Optimize strategies to improve post-exposure vaccine induced protection against tuberculosis with regards to administration route, timing of immunizations, antigen dose

Billeskov R, Elvang TT, Andersen P, Dietrich J The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One.2012; 7(6), e39909 PubMed
Aagaard C, Hoang TTKT, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med.2011; 17(2), 189-194 PubMed
Billeskov R, Grandal MV, Poulsen C, Christensen JP, Winther N, Vingsbo-Lundberg C, Hoang TT, van Deurs B, Song YH, Aagaard C, Andersen P, Dietrich J Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis. Eur J Immunol.2010; 40(5), 1342-1354 PubMed
Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J Induction of CD8 T Cells against a Novel Epitope in TB10.4: Correlation with Mycobacterial Virulence and the Presence of a Functional Region of Difference-1. J Immunol.2007; 179(6), 3973-3981
Billeskov R Characterisation of the immune response against Mycobacterium tuberculosis antigen TB10.4 in mice. University of Copenhagen. 2006;